al001
mAbexperimental
Clinical trial activity
9 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Sep 14, 2018 (NCT03636204)
Timeline
Indications
Mechanism of action
- Neurotensin receptor 3INHIBITOR
SORT1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650439 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06921590 | Phase 1 | May 9, 2025 | Alzamend Neuro, Inc., Harvard University |
| NCT06839339 | Phase 2 | Feb 18, 2025 | Government of China |
| NCT06111014 | Phase 3 | Dec 8, 2023 | Alector Inc. |
| NCT06707753 | Phase 1/Phase 2 (Phase 2) | Sep 11, 2023 | Government of China |
| NCT05363293 | Phase 1/Phase 2 (Phase 2) | May 4, 2022 | Alzamend Neuro, Inc. |
| NCT05053035 | Phase 2 | Sep 2, 2021 | Alector Inc., Harvard University |
| NCT04374136 | Phase 3 | Jul 30, 2020 | Alector Inc., University of California, San Francisco |
| NCT03987295 | Phase 2 | Jul 1, 2019 | Alector Inc., University of California, San Francisco |
| NCT03636204 | Phase 1 | Sep 14, 2018 | Alector Inc., BioClinica, Inc. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alector Inc. | For profit | 5 | 5 | 3 | 2018 |
| Alzamend Neuro, Inc. | For profit | 2 | 2 | 2 | 2022 |
| Government of China | Government | 2 | 2 | 1 | 2023 |
| Harvard University | Academic/Hospital | 2 | 0 | 2 | 2021 |
| University of California, San Francisco | Academic/Hospital | 2 | 0 | 2 | 2019 |
| BioClinica, Inc. | For profit | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1